(Q34609376)

English

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial (English)

1 reference

Europe PubMed Central

3 August 2017

phase III clinical trial

0 references

0 references

multicenter clinical trial

0 references

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Robert Landewé

4

object named as

Robert Landewé

1 reference

Europe PubMed Central

3 August 2017

object named as

Jonathan Kay

2

0 references

1

object named as

Josef S Smolen

1 reference

Europe PubMed Central

3 August 2017

13

object named as

Mahboob U Rahman

1 reference

Europe PubMed Central

3 August 2017

author name string

Mittie K Doyle

3

1 reference

Europe PubMed Central

3 August 2017

Eric L Matteson

5

1 reference

Europe PubMed Central

3 August 2017

Jürgen Wollenhaupt

6

1 reference

Europe PubMed Central

3 August 2017

Norman Gaylis

7

1 reference

Europe PubMed Central

3 August 2017

Frederick T Murphy

8

1 reference

Europe PubMed Central

3 August 2017

Jeffrey S Neal

9

1 reference

Europe PubMed Central

3 August 2017

Yiying Zhou

10

1 reference

Europe PubMed Central

3 August 2017

Sudha Visvanathan

11

1 reference

Europe PubMed Central

3 August 2017

Elizabeth C Hsia

12

1 reference

Europe PubMed Central

3 August 2017

GO-AFTER study investigators

14

1 reference

Europe PubMed Central

3 August 2017

language of work or name

0 references

publication date

26 June 2009

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

374

1 reference

Europe PubMed Central

3 August 2017

9685

1 reference

Europe PubMed Central

3 August 2017

210-221

1 reference

Europe PubMed Central

3 August 2017

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Fatigue in cancer patients compared with fatigue in the general United States population.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960506-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60506-7

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34609376&oldid=1978034981"